UTHR (United Therapeutics Corporation) Stock Financials & Earnings

UTHRUnited Therapeutics Corporation

Mkt Cap$24B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$3.2B

Net Income (TTM)$1.3B

EPS (TTM)$27.86

Free Cash Flow (TTM)$1.0B

Gross Margin87.9%

Op. Margin46.9%

Net Margin41.9%

FCF Margin32.7%

P/S Ratio (TTM)7.5x

P/E Ratio (TTM)17.9x

YoY Rev Growth+10.6%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$507M	$455M	$284M
Q2 23	$597M	$532M	$313M
Q3 23	$609M	$539M	$327M
Q4 23	$615M	$544M	$260M
Q1 24	$678M	$605M	$356M
Q2 24	$715M	$637M	$320M
Q3 24	$749M	$666M	$343M
Q4 24	$736M	$660M	$358M
Q1 25	$794M	$702M	$383M
Q2 25	$799M	$711M	$365M
Q3 25	$800M	$699M	$389M
Q4 25	$790M	$687M	$357M

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$83M	$70M	$17M	—
Q2 23	$89M	$110M	$20M	—
Q3 23	$85M	$107M	$21M	—
Q4 23	$151M	$108M	$24M	—
Q1 24	$104M	$121M	$23M	—
Q2 24	$140M	$152M	$25M	—
Q3 24	$104M	$199M	$21M	—
Q4 24	$134M	$136M	$27M	—
Q1 25	$149M	$144M	$27M	—
Q2 25	$134M	$160M	$31M	—
Q3 25	$128M	—	—	$183M
Q4 25	$140M	—	—	$212M

Revenue Segments

Quarter	Adcirca	Orenitram	Product and Service, Other	Remodulin	Tyvaso	Unituxin	Tyvaso Member
Q1 23	$7M	$88M	$3M	$121M	$238M	$49M	—
Q2 23	$8M	$95M	$4M	$127M	$319M	$44M	—
Q3 23	$7M	$92M	$2M	$131M	$205M	$51M	$121M
Q1 24	$6M	$106M	$6M	$128M	$373M	$58M	—
Q2 24	$6M	$107M	$5M	$147M	$398M	$52M	—
Q3 24	$7M	$113M	$6M	$128M	$434M	$61M	—
Q4 24	$5M	$108M	$6M	$135M	$416M	$68M	—
Q1 25	$6M	$121M	$5M	$138M	$466M	$58M	—
Q2 25	$7M	$124M	$6M	$135M	$470M	$58M	—
Q3 25	$10M	$131M	$7M	$126M	$478M	$48M	—
Q4 25	$8M	$121M	$7M	$128M	$464M	$62M	—

Revenue by Geography

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$1.2B	$1.7B	$2.9B
Q2 23	$1.1B	$1.6B	$2.7B
Q3 23	$1.1B	$1.8B	$2.9B
Q4 23	$1.2B	$1.8B	$3.0B
Q1 24	$1.3B	$1.5B	$2.7B
Q2 24	$1.4B	$1.6B	$3.0B
Q3 24	$1.6B	$1.8B	$3.3B
Q4 24	$1.7B	$1.6B	$3.3B
Q1 25	$1.9B	$1.4B	$3.3B
Q2 25	$1.6B	$1.5B	$3.0B
Q3 25	$1.1B	$1.6B	$2.8B
Q4 25	$1.6B	$0	$1.6B

Shares Outstanding

Revenue Per Employee

Revenue / Employee